Objective: To report the first known use of 5f-P22, 2-aminoindane (5IAI) and diclazepam in France in 2013

Case report: A 34 year Caucasian male presented to our Emergency Department (ED), one hour after ingesting two pills sold on the Internet for “Laboratory Reagent Use”.

Clinical examination showed an anxious patient, blood pressure (BP) was 135/73 mmHg, heart rate (HR) 110 bpm, SpO2 99 %. Electrocardiography (ECG) was normal. Temperature was 37 °C. Dextrose was 6 mmol/l. Biology was unremarkable. He was discharged the same day.

The first pill was green, in a bag, with a picture of the molecule and the formula:
7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one.
Name Diclazepam (chlorodiazepam) which is a Benzodiazapine.

The other pill was rose-red, with a mention of the name:
2-3-dihydro-1H-inden-2-amine, CAS: 2975-41-9 sold as 5IAI corresponding to 2 aminoindane (MPA) which is an Amphetamine with MDMA like-effects.

A week later, the same patient came again to our ED, one hour after smoking a beige powder. After dizziness and soporific state at home, the patient was alert with mydriasis; BP was 120/70 mmHg, HR 100 bpm, SpO2 99 %. ECG was normal. Temp was 36°C. Dextrose was 6.7 mmol/l. ECG was normal.

Mentioned on this new bag were:
quinolin-8-yl-(5-fluoropentyl)-1H-indole-3-carboxylate, CAS number: 14000742-41-7.
Name 5f-pb22 and drawing of the molecule It is a new Synthetic Cannabinoid of the JWH series, CP series or AM series.

Discussion:
Synthetic cannabinoids are used as Herbal (legal) Highs. Particulars effects such as agitation, aggression, sweating, logorrhoea are due to a stronger affinity for CB1 and CB2 receptors; tachycardia and mydriasis are usual. A few milligrams can induce clinical signs. Duration of effects is not well known except for THC. 5f-pb22 is a new synthetic Cannabinoid of the JWH series, CP series or AM series, with a fluorinated side chain as AM 694. Identification of these synthetic cannabinoids ( powder or in blood samples) is difficult, needing a high tech laboratory with magnetic resonance spectroscopy (NMR).

Diclazepam is a benzodiazepine, not marketed as medication, estimated to be ten-fold more active than diazepam.
5IAI synthesised in 1942, and used as stimulant drug since 2010 is well described in publications since 2013.
These drugs (non scheduled in France) are the subject of reports to French Pharmacodependance Centers and the Observatoire Français des Drogues et des toxicomanies (OFDT).

Conclusion:
New drugs can induce particular clinical signs. Neurological signs may be more pronounced after synthetic cannabinoid exposure. New drugs are now sold for laboratory reagent use, Laboratory investigations are difficult.

References:

Author mail: fgrossenbacher@chu-reims.fr

EAPCCT 2014 Congress
BRUXELLES